PrecisionLife
Andy Malinowski, PhD is a Principal Disease Biologist at PrecisionLife where Andy develops drug discovery programs for genetics-derived targets linked to specific patient subgroups within chronic diseases. With a background in stem cells and epigenetics, Andy has held positions at Novo Nordisk, Helmhzentrum München, Imperial College London, and MRC London Institute of Medical Sciences, focusing on areas such as genomics, pharmacology, and cell signaling. Their work includes creating in vitro models, effect testing of small molecules/ligands, and studying cell-cell communication.
This person is not in the org chart
PrecisionLife
Our unique approach powers an Innovation Engine creating new treatment opportunities for precision biopharma and healthcare.We generate the deepest understanding of the biology driving chronic diseases, stratifying patient populations at an unprecedented resolution to define new subgroups of patients.With these insights we discover novel drugtargets, drug repositioning candidates, and biomarkers to identify the patients who will benefit from them.#techbio #precisionmedicine